English Archives | SenzaGen

Correction: SenzaGen’s interim report January–June 2026 | Continued strong development in Q2 2026 – 13% growth with positive cash flow

Invitation to the presentation of SenzaGen’s January-June 2026 interim report

SenzaGen’s subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million

EU presents roadmap to phase out animal testing – strengthens SenzaGen’s long-term market potential

Report from AGM of SenzaGen AB on 12 May 2026

SenzaGen’s interim report January–March 2026 | 10% sales growth alongside increased attention to non-animal methods

Invitation to the presentation of SenzaGen’s January-March 2026 interim report

SenzaGen’s Annual Report 2025 published

SenzaGen’s subsidiary receives strategically important order

NOTICE OF ANNUAL GENERAL MEETING OF SENZAGEN AB (Publ)

Subscribe

Prenumerera